Current Edition

divestment

Novartis CEO Narashimhan confirms interest in purchase of generics unit Sandoz

Amid Novartis’ strategic review of generics unit Sandoz, last month came word that Swedish investment group EQT and the Struengmann brothers of Germany were considering …

Continue Reading →